2. Protein Tyrosine Kinase/RTK PI3K/Akt/mTOR Stem Cell/Wnt MAPK/ERK Pathway
  3. c-Met/HGFR Akt ERK
  4. SHR-A1403 Antibody

SHR-A1403 Antibody is an anti-c-Met monoclonal antibody. SHR-A1403 Antibody down-regulates phosphorylated c-Met, Akt, ERK, weakens intracellular signal cascades, and mediates antibody-c-Met complex endocytosis. SHR-A1403 Antibody can be used for the research of c-met-overexpressing cancers and pancreatic ductal adenocarcinoma.

For research use only. We do not sell to patients.

SHR-A1403 Antibody

SHR-A1403 Antibody Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

SHR-A1403 Antibody Related Antibodies

Top Publications Citing Use of Products

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SHR-A1403 Antibody is an anti-c-Met monoclonal antibody. SHR-A1403 Antibody down-regulates phosphorylated c-Met, Akt, ERK, weakens intracellular signal cascades, and mediates antibody-c-Met complex endocytosis. SHR-A1403 Antibody can be used for the research of c-met-overexpressing cancers and pancreatic ductal adenocarcinoma[1][2].

Isotype

Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity

Human
In Vitro

SHR-A1403 Antibody (SHR-A1403 mAb) binds with high affinity to human and cynomolgus monkey c-Met (Kd values of 1.58 × 10-8 M and 2.84 × 10-8 M, respectively) and does not bind mouse c-Met[1].
SHR-A1403 Antibody has low to no binding affinity to human Fc receptors and complement C1q, with measurable low affinity only for FcRn, FcγR I/CD64, and FcγR III/CD16[1].
SHR-A1403 Antibody (72 h) minimally inhibits proliferation of NCI-H1993, NCI-H441, A549, MKN-45, NCI-N87, Hs578T, PC-3, Caki-1, and HCCLM3 human cancer cell lines, with IC50 values greater than 5000 ng/mL[1].
SHR-A1403 Antibody (1 h) binds to human gastric cancer MKN-45 cells in a dose dependent manner[1].
SHR-A1403 Antibody (10-10000 ng/mL; 24 h) dose-dependently inhibits c-Met downstream signaling in human gastric cancer MKN-45 cells, reducing phosphorylated c-Met, Akt, and ERK levels[1].
SHR-A1403 Antibody (10 μg/mL; 1 h) is time-dependently internalized into human gastric cancer MKN-45 cells, reaching an endocytosis rate of ~30% after 3 h of incubation at 37 °C[1].
SHR-A1403 Antibody (1 μg/mL; 23 h) translocates to lysosomes in human gastric cancer MKN-45 cells[1].
SHR-A1403 Antibody (4 h) exhibits no detectable ADCC activity against human gastric cancer MKN-45 cells[1].
SHR-A1403 Antibody (15 min) exhibits low CDC activity against human gastric cancer MKN-45 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SHR-A1403 Antibody Related Antibodies

Western Blot Analysis[1]

Cell Line: human gastric cancer MKN-45 cells
Concentration: 10; 100; 1000; 10000 ng/mL
Incubation Time: 24 h
Result: Dose-dependently downregulated levels of phosphorylated c-Met, phosphorylated Akt, and phosphorylated ERK.
Showed equivalent potency to the ADC form of SHR-A1403 at the same concentrations.
Decreased total c-Met levels with increasing concentration.
In Vivo

SHR-A1403 mAb (10 mg/kg; i.v.; on days 0, 3, 7, 10, 14, 17) exhibits minor anti-tumor efficacy in HCCLM3 xenograft tumors in BALB/cA-nude mice, achieving a terminal TGI of 36%[1].
SHR-A1403 mAb (10 mg/kg; i.v.; on days 0, 3, 7, 10, 14, 17) exhibits minor anti-tumor efficacy in NCI-H1993 xenograft tumors in BALB/cA-nude mice, achieving a terminal TGI of 42%[1].
SHR-A1403 mAb (10 mg/kg; i.v.; single dose on day 0) exhibits moderate anti-tumor efficacy in MKN-45 xenograft tumors in BALB/cA-nude mice, achieving a terminal TGI of 45%[1].
SHR-A1403 mAb (10 mg/kg; i.v.; single dose) shows minimal anti-tumour activity in BALB/c nude mice bearing Aspc-1 pancreatic ductal adenocarcinoma xenografts[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/cA-nude mice (male, 6-7 weeks old) implanted with HCCLM3 tumor tissue[1]
Dosage: 10 mg/kg
Administration: i.v.; twice-weekly; on days 0, 3, 7, 10, 14, 17
Result: Achieved a terminal tumor growth inhibition (TGI) of 36%.
Reached a mean tumor volume of 1159 mm3 by day 17 post-treatment.
Confirmed the PDX tumor had high c-Met expression (IHC score 3+).
Caused no significant body weight loss.
Animal Model: BALB/cA-nude mice (male, 6-7 weeks old) implanted with NCI-H1993 tumor tissue[1]
Dosage: 10 mg/kg
Administration: i.v.; twice-weekly; on days 0, 3, 7, 10, 14, 17
Result: Achieved a terminal tumor growth inhibition (TGI) of 42%.
Caused no significant body weight loss.
Animal Model: BALB/cA-nude (male, 6-7 weeks old) implanted with MKN-45 tumor tissue[1]
Dosage: 10 mg/kg
Administration: i.v.; single dose on day 0
Result: Achieved a terminal tumor growth inhibition (TGI) of 45%.
Caused no significant body weight loss.
Animal Model: BALB/c nude mice (female, 4-6 weeks old) subcutaneously injected with spc-1 cells[2]
Dosage: 10 mg/kg
Administration: i.v.; single dose
Result: Showed a less pronounced reduction in subcutaneous tumour volume than SHR-A1403 (the ADC).
Exhibited no significant difference in tumour weight compared to control group.
Exhibited no significant difference in body weight compared to control group over the 21-day observation period.
Gene ID

4233  [NCBI]

Accession
Target

HGFR/c-Met
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

SHR-A1403 Antibody Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SHR-A1403 Antibodyc-Met/HGFRAktERKPKBProtein kinase BExtracellular signal regulated kinasespancreatic ductal adenocarcinomac-MetG2/M phase cell cycle arrestAspc-1cynomolgus monkeyapoptosisMKN-45mouseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SHR-A1403 Antibody
Cat. No.:
HY-P992464
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.